International Assets Investment Management LLC Has $147,000 Stake in Editas Medicine, Inc. (NASDAQ:EDIT)

International Assets Investment Management LLC raised its position in Editas Medicine, Inc. (NASDAQ:EDIT) by 10.5% during the second quarter, according to its most recent filing with the SEC. The firm owned 31,457 shares of the company’s stock after purchasing an additional 3,000 shares during the period. International Assets Investment Management LLC’s holdings in Editas Medicine were worth $147,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently modified their holdings of EDIT. Russell Investments Group Ltd. lifted its position in shares of Editas Medicine by 401.9% in the 4th quarter. Russell Investments Group Ltd. now owns 5,190 shares of the company’s stock worth $53,000 after purchasing an additional 4,156 shares during the period. Victory Capital Management Inc. acquired a new position in shares of Editas Medicine in the 4th quarter worth approximately $111,000. Jump Financial LLC lifted its position in shares of Editas Medicine by 42.0% in the 4th quarter. Jump Financial LLC now owns 28,159 shares of the company’s stock worth $285,000 after purchasing an additional 8,329 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of Editas Medicine by 40.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,392,396 shares of the company’s stock valued at $24,236,000 after acquiring an additional 690,366 shares during the period. Finally, Trexquant Investment LP lifted its position in shares of Editas Medicine by 28.9% during the 4th quarter. Trexquant Investment LP now owns 241,754 shares of the company’s stock valued at $2,449,000 after acquiring an additional 54,245 shares during the period. Institutional investors and hedge funds own 71.90% of the company’s stock.

Insider Buying and Selling

In other Editas Medicine news, CEO Gilmore Neil O’neill sold 12,191 shares of the stock in a transaction dated Tuesday, June 4th. The shares were sold at an average price of $5.50, for a total transaction of $67,050.50. Following the completion of the transaction, the chief executive officer now owns 315,279 shares in the company, valued at $1,734,034.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Editas Medicine news, EVP Linda Burkly sold 11,886 shares of the stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $5.42, for a total transaction of $64,422.12. Following the completion of the transaction, the executive vice president now owns 73,136 shares in the company, valued at $396,397.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Gilmore Neil O’neill sold 12,191 shares of the firm’s stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $5.50, for a total transaction of $67,050.50. Following the completion of the transaction, the chief executive officer now owns 315,279 shares of the company’s stock, valued at $1,734,034.50. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 31,207 shares of company stock worth $168,768. Insiders own 1.90% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on EDIT. Evercore ISI dropped their target price on shares of Editas Medicine from $15.00 to $7.00 and set an “in-line” rating on the stock in a research report on Thursday, May 30th. Morgan Stanley upgraded shares of Editas Medicine from an “underweight” rating to an “equal weight” rating and set a $7.00 target price on the stock in a research report on Thursday, May 9th. Bank of America upgraded shares of Editas Medicine from a “neutral” rating to a “buy” rating and boosted their target price for the company from $13.00 to $15.00 in a research report on Thursday, August 8th. Citigroup dropped their target price on shares of Editas Medicine from $16.00 to $15.00 and set a “buy” rating on the stock in a research report on Thursday, May 9th. Finally, Barclays dropped their target price on shares of Editas Medicine from $9.00 to $7.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 8th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $11.50.

Editas Medicine Stock Performance

NASDAQ EDIT opened at $3.74 on Monday. Editas Medicine, Inc. has a 52-week low of $3.62 and a 52-week high of $11.69. The company has a 50-day simple moving average of $4.69 and a 200 day simple moving average of $5.95. The company has a market capitalization of $308.48 million, a PE ratio of -1.78 and a beta of 2.01.

Editas Medicine (NASDAQ:EDIT) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.12). Editas Medicine had a negative return on equity of 62.61% and a negative net margin of 288.59%. The company had revenue of $0.51 million for the quarter, compared to analysts’ expectations of $4.78 million. During the same quarter last year, the business posted ($0.56) EPS. The business’s quarterly revenue was down 82.2% on a year-over-year basis. As a group, analysts forecast that Editas Medicine, Inc. will post -2.97 EPS for the current fiscal year.

About Editas Medicine

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.